Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 4
2005 2
2006 2
2007 2
2009 2
2010 3
2011 8
2012 4
2013 1
2014 5
2015 5
2016 10
2017 6
2018 2
2019 7
2020 12
2021 6
2022 5
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann O, Rijneveld AW, Rousselot P, Ribera JM, Bassan R. Gökbuget N, et al. Among authors: bassan r. Blood. 2024 Feb 2:blood.2023023568. doi: 10.1182/blood.2023023568. Online ahead of print. Blood. 2024. PMID: 38306595
Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.
Gökbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding AK, Foà R, Giebel S, Hoelzer D, Hunault M, Marks DI, Martinelli G, Ottmann OG, Rijneveld AW, Rousselot P, Ribera JM, Bassan R. Gökbuget N, et al. Among authors: bassan r. Blood. 2024 Jan 31:blood.2023020794. doi: 10.1182/blood.2023020794. Online ahead of print. Blood. 2024. PMID: 38295337
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
Foà R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, Ferrara F, Lunghi M, Mulè A, Bonifacio M, Fracchiolla N, Salutari P, Fazi P, Guarini A, Rambaldi A, Chiaretti S. Foà R, et al. Among authors: bassan r. J Clin Oncol. 2024 Mar 10;42(8):881-885. doi: 10.1200/JCO.23.01075. Epub 2023 Dec 21. J Clin Oncol. 2024. PMID: 38127722 Free PMC article.
A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.
Enshaei A, Joy M, Butler E, Kirkwood AA, Messina M, Pavoni C, Morgades M, Harrison CJ, Foà R, Ribera JM, Chiaretti S, Bassan R, Fielding AK, Moorman AV. Enshaei A, et al. Among authors: bassan r. Blood Adv. 2024 Mar 12;8(5):1155-1166. doi: 10.1182/bloodadvances.2023011661. Blood Adv. 2024. PMID: 38113467 Free PMC article.
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
Barilà G, Quaglia FM, Furlan A, Pescosta N, Bonalumi A, Marcon C, Pascarella A, Tinelli M, De March E, Lico A, Sartori R, Clissa C, De Sabbata G, Nappi D, Porrazzo M, De Marchi R, Pavan L, Tosetto A, Gherlinzoni F, Krampera M, Bassan R, Patriarca F, Semenzato G, Zambello R. Barilà G, et al. Among authors: bassan r. Ann Hematol. 2024 Jan;103(1):125-132. doi: 10.1007/s00277-023-05443-8. Epub 2023 Sep 20. Ann Hematol. 2024. PMID: 37731147 Free PMC article.
Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
Cardinali D, Beldinanzi M, Ansuinelli M, Elia L, Della Starza I, Bellomarino V, Matarazzo M, Di Trani M, Cola M, Salutari P, Cedrone M, Bassan R, De Gobbi M, Della Porta MG, De Simone M, Alati C, Fracchiolla NS, Lunghi M, Intermesoli T, Cardinali V, Mulè A, Guarini A, Foà R, Chiaretti S. Cardinali D, et al. Among authors: bassan r. Leuk Lymphoma. 2023 Nov-Dec;64(11):1884-1887. doi: 10.1080/10428194.2023.2235450. Epub 2023 Jul 15. Leuk Lymphoma. 2023. PMID: 37452789 No abstract available.
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.
Bassan R, Chiaretti S, Della Starza I, Spinelli O, Santoro A, Paoloni F, Messina M, Elia L, De Propris MS, Scattolin AM, Audisio E, Marbello L, Borlenghi E, Zappasodi P, Mauro E, Martinelli G, Mattei D, Fracchiolla N, Bocchia M, De Fabritiis P, Bonifacio M, Candoni A, Cassibba V, Di Bartolomeo P, Latte G, Trappolini S, Guarini A, Vitale A, Fazi P, Piciocchi A, Rambaldi A, Foà R. Bassan R, et al. Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596. Blood Adv. 2023. PMID: 37276451 Free PMC article.
Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study.
Boissel N, Chiaretti S, Papayannidis C, Ribera JM, Bassan R, Sokolov AN, Alam N, Brescianini A, Pezzani I, Kreuzbauer G, Zugmaier G, Foà R, Rambaldi A. Boissel N, et al. Among authors: bassan r. Blood Cancer J. 2023 Jan 4;13(1):2. doi: 10.1038/s41408-022-00766-7. Blood Cancer J. 2023. PMID: 36599847 Free PMC article.
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings.
Chiaretti S, Taherinasab A, Della Starza I, Canichella M, Ansuinelli M, De Propris MS, Messina M, Spinelli O, Santoro A, De Novi LA, Cardinali D, Schipani M, Arena V, Bassan R, Guarini A, Foà R. Chiaretti S, et al. Among authors: bassan r. Leuk Lymphoma. 2023 Feb;64(2):483-486. doi: 10.1080/10428194.2022.2148217. Epub 2022 Dec 19. Leuk Lymphoma. 2023. PMID: 36533589 No abstract available.
89 results